Working closely with researchers from the Flint Animal Cancer Center at Colorado State University, VetDC was established to identify and evaluate novel anti-cancer therapies and advance them rapidly in pets. VetDC is focusing on innovative, cutting-edge programs that were initially designed for humans, but were subsequently found to demonstrate promising benefits in companion animals.
When it comes to cancer, pets deserve access to the most advanced, scientifically rigorous treatments available today. VetDC is committed to bringing novel therapies to the veterinary community, giving veterinarians, pet owners and their beloved family members new options and hope for cancer treatment for dogs.
Tanovea-CA-1 is designed to target and attack lymphoma cells and is the first FDA conditionally approved drug for the treatment of lymphoma in dogs. VDC-597 is a targeted anti-cancer drug for various tumors.
For more information about VetDC visit www.vetdc.com.